The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Official Title: An Open-Label, Phase 1/1b, Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Study ID: NCT05413421
Brief Summary: The purpose of this study is to establish recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) and preliminary antitumor activity of ORIC-944 in patients with metastatic prostate cancer.
Detailed Description: ORIC-944 is a potent, highly selective, allosteric, orally bioavailable, small molecule inhibitor of PRC2 via binding the embryonic ectoderm development (EED) subunit. This is a first-in-human, open-label, single arm, multicenter, dose escalation followed by dose expansion study to establish the recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) and preliminary antitumor activity of ORIC-944 in patients with metastatic prostate cancer, including those with neuroendocrine and/or small cell features, who have exhausted available treatment options. The study will begin with dose finding in patients with metastatic prostate cancer (Dose Escalation); additional dose expansion cohorts (Dose Expansion), with specific histology, treatment history, and/or expression of a specific biomarker, may be initiated via protocol amendment The study will evaluate escalating dose levels of ORIC-944 administered orally, once daily in 28-day cycles following an interval 3+3 design.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Karmanos, Detroit, Michigan, United States
Memorial Sloane Kettering Cancer Center, New York, New York, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
Keystone Urology Specialists, Lancaster, Pennsylvania, United States
Urology Clinics of North Texas, Dallas, Texas, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Name: Pratik S. Multani, MD
Affiliation: ORIC Pharmaceuticals
Role: STUDY_DIRECTOR